Robert E Coleman

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
    Robert Coleman
    CR UK YCR Sheffield Cancer Research Centre, Weston Park Hospital, University of Sheffield, Sheffield, UK Electronic address
    Lancet Oncol 15:997-1006. 2014
  2. pmc Bone loss and the aromatase inhibitors
    J Lester
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Br J Cancer 93:S16-22. 2005
  3. pmc A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
    Robert Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield Cancer Research Centre, Sheffield, S10 2SJ, England, UK
    Breast Cancer Res Treat 145:411-8. 2014
  4. pmc Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
    J E Lester
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Br J Cancer 94:30-5. 2006
  5. pmc Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease
    L Walkington
    Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
    Br J Cancer 104:1665-9. 2011
  6. pmc Bone resorption predicts for skeletal complications in metastatic bone disease
    J E Brown
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Br J Cancer 89:2031-7. 2003
  7. ncbi The metastatic microenvironment of breast cancer: clinical implications
    R E Coleman
    Academic Unit of Clinical Oncology, CR UK YCR Sheffield Cancer Research Centre, Weston Park Hospital, Witham Road, Sheffield S10 2SJ, UK Electronic address
    Breast 22:S50-6. 2013
  8. doi Management of cancer treatment-induced bone loss
    Robert E Coleman
    Academic Unit of Oncology, Sheffield Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
    Nat Rev Rheumatol 9:365-74. 2013
  9. doi Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
    R Coleman
    Academic Unit of Clinical Oncology, CR UK YCR Sheffield Cancer Research Centre, Sheffield, UK
    Ann Oncol 24:398-405. 2013
  10. doi Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study
    Robert E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, CR UK YCR Sheffield Cancer Research Centre, Sheffield, UK
    Curr Opin Support Palliat Care 6:322-9. 2012

Detail Information

Publications107 found, 100 shown here

  1. ncbi Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
    Robert Coleman
    CR UK YCR Sheffield Cancer Research Centre, Weston Park Hospital, University of Sheffield, Sheffield, UK Electronic address
    Lancet Oncol 15:997-1006. 2014
    ..We therefore did a large randomised trial to investigate the effect of the adjuvant use of zoledronic acid on disease-free survival (DFS) in high-risk patients with early breast cancer...
  2. pmc Bone loss and the aromatase inhibitors
    J Lester
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Br J Cancer 93:S16-22. 2005
    ..Strategies for the identification and management of treatment-induced bone loss are currently being defined...
  3. pmc A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
    Robert Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield Cancer Research Centre, Sheffield, S10 2SJ, England, UK
    Breast Cancer Res Treat 145:411-8. 2014
    ..5 % mRR at week 17). Radium-223 was safe and well tolerated. Radium-223 targets areas of increased bone metabolism and shows biological activity in advanced breast cancer patients with bone-dominant disease. ..
  4. pmc Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
    J E Lester
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Br J Cancer 94:30-5. 2006
    ..The development of national guidelines for the management of these patients and educational initiatives for breast teams are urgently required...
  5. pmc Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease
    L Walkington
    Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
    Br J Cancer 104:1665-9. 2011
    ..Hyperthyroidism usually resolves as the GTD is successfully treated and correspondingly HCG levels normalise...
  6. pmc Bone resorption predicts for skeletal complications in metastatic bone disease
    J E Brown
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Br J Cancer 89:2031-7. 2003
    ..N-telopeptide appears useful in the prediction of patients most likely to experience skeletal complications and thus benefit from bisphosphonate treatment...
  7. ncbi The metastatic microenvironment of breast cancer: clinical implications
    R E Coleman
    Academic Unit of Clinical Oncology, CR UK YCR Sheffield Cancer Research Centre, Weston Park Hospital, Witham Road, Sheffield S10 2SJ, UK Electronic address
    Breast 22:S50-6. 2013
    ..82; 95%CI 0.74-0.92, 2P = <0.001), with reductions in relapse rates not only in bone but also at extra-skeletal and loco-regional sites. These exciting findings are beginning to change clinical practice...
  8. doi Management of cancer treatment-induced bone loss
    Robert E Coleman
    Academic Unit of Oncology, Sheffield Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
    Nat Rev Rheumatol 9:365-74. 2013
    ..These bone-targeted treatments have also been shown to modify the course of the underlying cancer and prevent metastasis, although the beneficial effects are confined to patients with low levels of circulating reproductive hormones...
  9. doi Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
    R Coleman
    Academic Unit of Clinical Oncology, CR UK YCR Sheffield Cancer Research Centre, Sheffield, UK
    Ann Oncol 24:398-405. 2013
    ..Although generally more effective than tamoxifen, aromatase inhibitor therapy is associated with increased bone loss and fracture risk...
  10. doi Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study
    Robert E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, CR UK YCR Sheffield Cancer Research Centre, Sheffield, UK
    Curr Opin Support Palliat Care 6:322-9. 2012
    ..Additionally, these drugs may modify the course of bone destruction via inhibitory effects on the 'vicious cycle' of growth factor and cytokine signalling between tumour and bone cells within the bone marrow microenvironment...
  11. doi Effects of bone-targeted agents on cancer progression and mortality
    Robert Coleman
    Academic Unit of Clinical Oncology, Broomcross Building, Weston Park Hospital, Sheffield S10 2SJ, UK
    J Natl Cancer Inst 104:1059-67. 2012
    ..Here, we have critically reviewed the increasing evidence to support a disease-modifying effect of bone-targeted treatment and discussed the impact on clinical management...
  12. doi Consensus on the utility of bone markers in the malignant bone disease setting
    Robert Coleman
    Cancer Research Centre, Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Whitham Road, Sheffield, England, UK
    Crit Rev Oncol Hematol 80:411-32. 2011
    ..Results from ongoing clinical trials evaluating such potential applications of bone markers are awaited...
  13. ncbi Bone cancer in 2011: Prevention and treatment of bone metastases
    Robert E Coleman
    Sheffield Cancer Research Center, Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
    Nat Rev Clin Oncol 9:76-8. 2012
    ....
  14. pmc The present and future role of bisphosphonates in the management of patients with breast cancer
    Janet E Brown
    Yorkshire Cancer Research Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    Breast Cancer Res 4:24-9. 2002
    ..Ongoing research is aimed at trying to define the optimum route, dose, schedule and type of bisphosphonate...
  15. pmc Study protocol to investigate the effect of a lifestyle intervention on body weight, psychological health status and risk factors associated with disease recurrence in women recovering from breast cancer treatment [ISRCTN08045231]
    John M Saxton
    Centre for Sport and Exercise Science, Sheffield Hallam University, Sheffield, UK
    BMC Cancer 6:35. 2006
    ....
  16. pmc Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity
    Pierre P Major
    McMaster University, Juravinski Cancer Centre, Hamilton, Ontario, Canada
    BMC Cancer 9:272. 2009
    ..Because many patients with cancer die before trial completion, there is a need for survival-adjusted methods to accurately assess the effects of treatment on skeletal morbidity...
  17. ncbi Clinical features of metastatic bone disease and risk of skeletal morbidity
    Robert E Coleman
    Academic Unit of Medical Oncology, Weston Park Hospital, Sheffield, United Kingdom
    Clin Cancer Res 12:6243s-6249s. 2006
    ..Our improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources...
  18. pmc Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference
    Robert E Coleman
    The University of Sheffield Cancer Research Centre, Sheffield, UK
    Clin Cancer Res 14:6387-95. 2008
    ..Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer...
  19. ncbi Conclusion: Bone markers in metastatic bone disease
    Robert E Coleman
    Cancer Research Centre, Academic Unit of Clinical Oncology, Broomcross Building, Weston Park Hospital, Sheffield S10 2SJ, UK
    Cancer Treat Rev 32:27-8. 2006
    ..In this conclusion, we summarise data from leading studies relating to the search for useful markers of bone resorption and bone formation in MBD...
  20. ncbi The role of bone markers in metastatic bone disease
    Robert E Coleman
    Cancer Research Centre, Academic Unit of Clinical Oncology, Broomcross Building, Weston Park Hospital, Sheffield S10 2SJ, UK
    Cancer Treat Rev 32:1-2. 2006
    ..Bone markers are also being evaluated as a possible guide to optimize treatment of bone complications. In the reports included in this supplement, experts at the frontiers of bone marker research offer insights on their progress...
  21. ncbi A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)
    R E Coleman
    Cancer Research Centre, YCR Department of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
    Eur J Cancer 42:882-7. 2006
    ..The high frequency of stomatitis seen with 6 weekly treatment makes this the less preferred of the two schedules tested...
  22. pmc The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
    R E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK
    Br J Cancer 102:1099-105. 2010
    ..We report a retrospective evaluation comparing pathological response in the primary tumour between treatment groups...
  23. doi New results from the use of bisphosphonates in cancer patients
    Robert Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, WhithamRoad, Sheffield S103LZ, UK
    Curr Opin Support Palliat Care 3:213-8. 2009
    ..Additionally, cancer treatments may have adverse effects on bone health. Therefore, a clear rationale exists for bone-targeted therapies to prevent skeletal complications and potentially modify the underlying disease...
  24. ncbi Emerging strategies in bone health management for the adjuvant patient
    Robert E Coleman
    Cancer Research Centre, Head, Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK
    Semin Oncol 34:S11-6. 2007
    ..Biochemical markers of bone turnover and tumor markers are being characterized and may provide useful tools to identify high-risk patients who may especially benefit from bisphosphonate therapy...
  25. ncbi Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies
    Robert E Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom
    Cancer Treat Rev 34:S31-42. 2008
    ....
  26. ncbi On the horizon: can bisphosphonates prevent bone metastases?
    R Coleman
    Weston Park Hospital, Cancer Research Centre, Academic Unit of Clinical Oncology, Sheffield, UK
    Breast 16:S21-7. 2007
    ..Therefore, patients with early-stage disease may benefit from early bisphosphonate therapy, before bone metastasis develops, and investigations are ongoing to determine the clinical utility of bisphosphonates in this setting...
  27. pmc Risks and benefits of bisphosphonates
    R E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, UK
    Br J Cancer 98:1736-40. 2008
    ..The incidence, clinical importance and prevention strategies to minimise the impact of this problem on patients requiring bisphosphonates is discussed...
  28. pmc Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions
    Robert Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Cancer Treat Rev 34:629-39. 2008
    ..Biochemical markers of bone metabolism may meet an unmet need for useful, noninvasive, and sensitive surrogate information for following patients' skeletal health...
  29. ncbi The benefits and costs of bisphosphonates
    Robert E Coleman
    University of Sheffield, Hospital, Sheffield, United Kingdom
    J Support Oncol 5:483-4. 2007
  30. ncbi Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer
    Robert Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    Clin Breast Cancer 7:S29-35. 2007
    ....
  31. ncbi Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
    R E Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital NHS Trust, Sheffield, UK
    Eur J Cancer 45:1909-15. 2009
    ..The results of ongoing large metastasis prevention trials are however, required before routine use of adjuvant bisphosphonates can be recommended...
  32. ncbi Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
    Robert E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK
    Lancet Oncol 8:119-27. 2007
    ....
  33. ncbi The role of bisphosphonates in breast cancer
    Robert E Coleman
    Cancer Research Centre, YCR Academic Unit of Oncology, Weston Park Hospital, Sheffield, S10 2SJ, UK
    Breast 13:S19-28. 2004
    ..On the basis of these results, zoledronic acid has rapidly become the new international standard of care for patients with bone metastases from breast cancer...
  34. pmc Treatment and secondary prevention of venous thromboembolism in cancer
    R Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
    Br J Cancer 102:S17-23. 2010
    ..This article, which is the third of four articles covering key topics in cancer thrombosis, focuses on treatment and secondary prevention of VTE in cancer patients...
  35. doi Bisphosphonates in oncology
    Robert E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK
    Bone 49:71-6. 2011
    ..In comparison to most other cancer treatments, adverse events related to bisphosphonate therapy are generally mild and infrequent; thus, the benefits of treatment within licensed indications will almost always outweigh the risks...
  36. doi Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer
    R Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, S10 2SJ, UK
    Breast Cancer Res Treat 127:429-38. 2011
    ..ZOL in the adjuvant setting is well tolerated, and can be safely administered in addition to adjuvant therapy including chemotherapy. The adverse events were consistent with the known safety profile of ZOL, with a low incidence of ONJ...
  37. ncbi Hormone- and chemotherapy-induced bone loss in breast cancer
    Robert E Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England, United Kingdom
    Oncology (Williston Park) 18:16-20. 2004
    ..Thus other strategies to protect bone are needed. This article discusses various treatments that attempt to offset this bone loss--mainly the protective effects of several bisphosphonates...
  38. ncbi Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations
    R E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, Witham Road, Sheffield S10 2SJ, UK
    Cancer Treat Rev 34:275-82. 2008
    ..Knowing that joint symptoms can be managed in most patients may encourage patient-physician communication and treatment compliance...
  39. ncbi Breast-cancer adjuvant therapy with zoledronic acid
    Robert E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, United Kingdom
    N Engl J Med 365:1396-405. 2011
    ..We conducted a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant therapy, would improve disease outcomes in such patients...
  40. ncbi Management of bone metastases
    R E Coleman
    Yorkshire Cancer Research Department of Clinical Oncology, Cancer Research Center, Weston Park Hospital, Sheffield, England
    Oncologist 5:463-70. 2000
    ....
  41. ncbi Current and future status of adjuvant therapy for breast cancer
    Robert E Coleman
    Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom
    Cancer 97:880-6. 2003
    ..It may be possible to replace the current oral regimens for prevention of bone loss with a single annual infusion of the highly potent bisphosphonate zoledronic acid...
  42. ncbi The clinical use of bone resorption markers in patients with malignant bone disease
    Robert E Coleman
    Cancer Research Centre, YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, S10 2SJ, UK
    Cancer 94:2521-33. 2002
    ..Biochemical markers of bone resorption have been identified that can augment the imaging techniques used to diagnose bone metastases and assess response to bisphosphonate therapy...
  43. ncbi Bisphosphonates: clinical experience
    Robert E Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield, England S10 2SJ, United Kingdom
    Oncologist 9:14-27. 2004
    ....
  44. ncbi Managing metastatic bone disease: three case studies
    Robert Coleman
    Yorkshire Cancer Research Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    Semin Oncol 31:83-6. 2004
    ..The third case history illustrates the benefits of rapid pain relief from an intensive, high-dose regimen of intravenous ibandronate in metastatic prostate cancer...
  45. ncbi Zoledronic acid use in cancer patients: more than just supportive care?
    Robert Coleman
    Cancer Research Centre, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom
    Cancer 117:11-23. 2011
    ..Ongoing clinical trials in patients with solid tumors will provide further insight into the potential of ZOL to prevent distant metastases and improve survival...
  46. doi Zoledronic acid
    Robert Coleman
    University of Sheffield, Weston Park Hospital, Academic Unit of Clinical Oncology, Sheffield, UK
    Expert Opin Drug Saf 10:133-45. 2011
    ..Zoledronic acid is a widely used intravenous bisphosphonate that reduces this skeletal morbidity in both benign and malignant conditions...
  47. ncbi Bisphosphonates in breast cancer
    R E Coleman
    Academic Unit of Clinical Oncology, Yorkshire Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    Ann Oncol 16:687-95. 2005
    ..Preclinical data suggest that bisphosphonates have antitumour effects. Bisphosphonates may also be of use in the adjuvant setting...
  48. doi The use of bisphosphonates in cancer treatment
    Robert Coleman
    Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom
    Ann N Y Acad Sci 1218:3-14. 2011
    ..In addition, they are increasingly used to prevent cancer treatment-induced bone loss and show promise in the adjuvant setting to prevent metastasis from breast cancer...
  49. pmc Metastasis and bone loss: advancing treatment and prevention
    Robert E Coleman
    Yorkshire Cancer Research Professor of Medical Oncology, Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S102SJ, UK
    Cancer Treat Rev 36:615-20. 2010
    ....
  50. ncbi Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    Robert E Coleman
    Yorkshire Cancer Research Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, England, UK
    J Clin Oncol 23:4925-35. 2005
    ..These trials provide an opportunity for investigating the correlation between bone metabolism and clinical outcome during bisphosphonate therapy...
  51. doi Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study
    Robert E Coleman
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    Breast Cancer Res Treat 124:153-61. 2010
    ..With the switch strategy used in IES, the on treatment adverse bone effects of exemestane are reversed. Ongoing monitoring of BMD is therefore not routinely required...
  52. ncbi Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
    Janet E Brown
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England, United Kingdom
    J Natl Cancer Inst 97:59-69. 2005
    ..We investigated this question in patients with bone metastases secondary to prostate cancer and to non-small-cell lung cancer (NSCLC) and other solid tumors assigned to the placebo arms of two phase III trials of zoledronic acid...
  53. ncbi Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone
    Penelope D Ottewell
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
    Mol Cancer Ther 8:2821-32. 2009
    ..Our data are the first to show the specific molecular pathways by which sequential treatment with doxorubicin and zoledronic acid induce tumor cell apoptosis and inhibit proliferation in an in vivo model of breast tumor growth in bone...
  54. doi Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer
    James E Lester
    Academic Unit of Clinical Oncology, Weston Park Hospital and Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom
    Clin Cancer Res 14:6336-42. 2008
    ..The ARIBON trial is a double-blind, randomized, placebo-controlled study designed to evaluate the impact of bisphosphonate treatment on bone mineral density (BMD) in women taking anastrozole...
  55. doi Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice
    Penelope D Ottewell
    Academic Unit of Clinical Oncology, Medical School, University of Sheffield, Sheffield, UK
    Breast Cancer Res Treat 133:523-36. 2012
    ..Combination treatment with doxorubicin followed by zoledronic acid inhibits development and progression of spontaneously occurring mammary tumours...
  56. doi Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model
    Penelope D Ottewell
    University of Sheffield, United Kingdom
    Int J Cancer 126:522-32. 2010
    ..Our data are the first to show a sustained antitumor effect in vivo following a limited course of sequential administration of doxorubicin followed by zoledronic acid...
  57. ncbi Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro
    Julia K L Woodward
    Academic Unit of Clinical Oncology, Genomic Medicine, Medical School, University of Sheffield, UK
    Anticancer Drugs 16:845-54. 2005
    ..For 10 microM zoledronic acid, pre- or post-doxorubicin also reduces invasion, but for this combination inhibition of cell growth may contribute to the reduction in invasion observed...
  58. doi Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?
    Maria Michailidou
    Academic Units of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    J Vasc Res 47:481-93. 2010
    ....
  59. doi Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study
    Matthew C Winter
    Academic Unit of Clinical Oncology, CR UK YCR Sheffield Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom
    Clin Cancer Res 19:2755-65. 2013
    ..To investigate the short-term biologic effects of neoadjuvant chemotherapy +/- zoledronic acid (ZOL) in invasive breast cancer...
  60. ncbi Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer
    Penelope D Ottewell
    Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
    J Natl Cancer Inst 100:1167-78. 2008
    ..We investigated the effects of clinically achievable doses of doxorubicin (Dox) and Zol, given alone, in sequence, and in combination, on the growth of established breast tumors in vivo...
  61. doi The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases
    Jim E Lester
    Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Bone 46:801-5. 2010
    ..Whilst POCDs appear to record higher values than laboratory assays, the correlation between devices is good and with further research the NTX categories could be modified to accommodate this variation...
  62. ncbi Bisphosphonates as treatment of bone metastases
    Ingunn Holen
    Academic Unit of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield, S10 2SJ, UK
    Curr Pharm Des 16:1262-71. 2010
    ..We also give an overview of the use of bisphosphonates in the treatment of breast cancer, including examples of key clinical trials. The potential side effects and future clinical applications of bisphosphonates will be outlined...
  63. doi Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients
    Janet E Brown
    Cancer Research UK Experimental Cancer Medicine Centres at Leeds and Sheffield, Cancer Research Centre, Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom
    Clin Cancer Res 18:6348-55. 2012
    ..We analyzed data from a phase III trial comparing zoledronic acid (ZOL) with pamidronate in patients with breast cancer and bone metastases to identify variables prognostic for overall survival...
  64. ncbi Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04)
    Emma J Rathbone
    Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, S10 2SJ, England
    J Clin Oncol 31:2685-91. 2013
    ..We report on the frequency of ONJ and investigate oral health-related quality of life (Oral-QoL) in a large randomized trial (Adjuvant Zoledronic Acid to Reduce Recurrence [AZURE])...
  65. ncbi Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
    Richard Eastell
    Academic Unit of Bone Metabolism, University of Sheffield, UK
    J Clin Oncol 26:1051-7. 2008
    ..It is therefore important to understand the effects of long-term aromatase inhibitor therapy on BMD...
  66. doi Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo
    Penelope D Ottewell
    School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
    Clin Cancer Res 14:4658-66. 2008
    ..We have therefore investigated the antitumor effects of clinically relevant doses of these drugs in a mouse model of breast cancer bone metastasis...
  67. ncbi Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
    Simon S Cross
    Academic Units of Clinical Oncology, Pathology and Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Int J Cancer 118:1901-8. 2006
    ..This is the first study to report the proangiogenic effects of OPG in vitro, as well as correlating expression of OPG by tumour endothelial cells with clinicopathological data in human tumours...
  68. doi Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
    Omar S Din
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, S10 2SJ, UK
    Breast Cancer Res Treat 120:525-38. 2010
    ..Radiological imaging and biochemical analyses may help our understanding of AIA and these are discussed...
  69. ncbi Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma
    Janet E Brown
    Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, UK
    Clin Cancer Res 12:6480-6. 2006
    ..This study assesses the extent of bone loss due to previous chemotherapy in men...
  70. ncbi The role of bisphosphonates in breast and prostate cancers
    Janet E Brown
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK
    Endocr Relat Cancer 11:207-24. 2004
    ..Several placebo-controlled trials using oral clodronate, oral risedronate, intravenous pamidronate and intravenous zoledronic acid have all now demonstrated benefits in reducing the loss in bone mineral density...
  71. doi Potential anticancer properties of bisphosphonates
    Helen L Neville-Webbe
    Cancer Research Centre, Weston Park Hospital, University of Sheffield, UK
    Semin Oncol 37:S53-65. 2010
    ..This review will focus on emerging evidence of the anticancer activities of bisphosphonates and possible underlying mechanisms of action...
  72. ncbi Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid
    Janet E Brown
    Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, United Kingdom
    Clin Cancer Res 13:5406-10. 2007
    ..With potent bisphosphonates, such as zoledronic acid, it may be possible to maintain efficacy with relatively infrequent administration...
  73. pmc Anti-tumour activity of bisphosphonates in preclinical models of breast cancer
    Ingunn Holen
    Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK
    Breast Cancer Res 12:214. 2010
    ..Evidence for effects on different processes and cell types involved in cancer development and progression is discussed, and the main outstanding issues identified...
  74. ncbi Bisphosphonates in breast cancer: teaching an old dog new tricks
    Matthew C Winter
    Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK to Top
    Curr Opin Oncol 21:499-506. 2009
    ..However, recent data suggest that bisphosphonate use in breast cancer may provide more than just supportive care and modify the course of the disease by disrupting the metastatic process...
  75. ncbi Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
    Helen L Neville-Webbe
    Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom
    Int J Cancer 113:364-71. 2005
    ..These findings may have relevance for the clinical setting, particularly breast cancer patients receiving these drugs in the adjuvant setting...
  76. doi The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells
    Hannah K Brown
    Academic Unit of Clinical Oncology, Medical School, University of Sheffield, Sheffield, UK
    J Cell Mol Med 15:501-13. 2011
    ..This is the first report showing a specific effect of zoledronic acid on a protein involved in the regulation of chromosome segregation, identifying Cenp-F as a potential new molecular target for NBPs in tumour cells...
  77. ncbi Deaths from gestational trophoblastic neoplasia: any lessons to be learned?
    Sarah J Kingdon
    Sheffield Centre for Trophoblastic Disease, Weston Park Hospital, Sheffield, UK
    J Reprod Med 57:293-6. 2012
    ..To review retrospectively the causes of death in unselected patients with gestational trophoblastic neoplasia (GTN)...
  78. ncbi Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion
    Julia K L Woodward
    Academic Unit of Clinical Oncology, Division of Genomic Medicine, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Anticancer Drugs 16:11-9. 2005
    ..This review discusses the preclinical evidence for the potential use of BPs and cytotoxic drugs for inhibiting tumor cell invasion, a key process in cancer progression...
  79. ncbi Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials
    Robert E Coleman
    Cancer Research Centre, YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
    Am J Clin Oncol 25:S25-31. 2002
    ....
  80. ncbi The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer
    Julia K L Woodward
    Academic Unit of Clinical Oncology, D Floor, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
    Bone 41:912-27. 2007
    ..The results from trials involving protease inhibitors in clinical development will also be briefly discussed...
  81. ncbi Bisphosphonates for the prevention of bone metastases
    Robert E Coleman
    Cancer Research Centre, YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK
    Semin Oncol 29:43-9. 2002
    ..Adjuvant studies of zoledronic acid in patients with breast cancer are in development and should further clarify the role of zoledronic acid in the prevention of bone metastases...
  82. ncbi Future directions in the treatment and prevention of bone metastases
    Robert E Coleman
    Cancer Research Centre, YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
    Am J Clin Oncol 25:S32-8. 2002
    ....
  83. doi Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study
    Diana M Greenfield
    Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, United Kingdom
    Cancer 116:1592-601. 2010
    ..The authors investigated the relationship between androgen levels, QOL, self-esteem, fatigue, and sexual function in young male cancer survivors compared with control subjects...
  84. ncbi Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Ingunn Holen
    Bone Oncology Group, Division of Genomic Medicine, University of Sheffield, Sheffield, UK
    Breast Cancer Res Treat 92:207-15. 2005
    ..To our knowledge these results are the first to demonstrate that OPG can act as an endocrine survival factor for breast cancer cells, as well as reporting the expression patterns of OPG in a large cohort of human breast tumours...
  85. ncbi Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia
    James Michael Price
    Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom
    J Reprod Med 55:301-4. 2010
    ....
  86. ncbi High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours
    Loaie M El-Helw
    Cancer Research Centre, Weston Park Hospital, Sheffield, UK
    BJU Int 98:519-25. 2006
    ....
  87. ncbi Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity
    Allan Lipton
    Milton S Hershey Medical Center, Penn State Cancer Institute, 500 University Drive, Hershey, Pennsylvania 17033, USA
    Oncologist 12:1035-43. 2007
    ....
  88. ncbi Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group
    David M Reid
    Department of Rheumatology, University of Aberdeen, United Kingdom
    Cancer Treat Rev 34:S3-18. 2008
    ..Management recommendations have been summarised in two algorithms, one for women experiencing a premature menopause and the other for postmenopausal women requiring adjuvant aromatase inhibitor therapy...
  89. ncbi Preserving skeletal wellness throughout the continuum of care in patients with cancer. Introduction
    Robert E Coleman
    Semin Oncol 34:S1-3. 2007
  90. doi Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
    Allan Lipton
    Department of Hematology Oncology, Milton S Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA
    Cancer 113:193-201. 2008
    ..For patients with bone metastases, high N-telopeptide of type I collagen (NTX) levels correlate with increased risks of skeletal-related events and death. However, the relation between NTX decreases and clinical benefits is unclear...
  91. ncbi Supportive care in oncology
    Robert E Coleman
    Support Care Cancer 13:959-60. 2005
  92. ncbi Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity
    Vera Hirsh
    McGill University Health Centre, Montreal, Quebec, Canada
    J Thorac Oncol 3:228-36. 2008
    ..Zoledronic acid (ZOL) reduces SRE risk and NTX levels...
  93. ncbi A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
    Jean Jacques Body
    Unit of Endocrinology, Institut Jules Bordet, Brussels, Belgium
    Cancer 97:887-92. 2003
    ..In binding to RANKL, OPG blocks differentiation and activation of osteoclasts. AMGN-0007 is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease...
  94. ncbi Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial
    Laura Biganzoli
    IDBBC Unit, EORTC IDBBC, Jules Bordet Institute, Boulevard de Waterloo 121, 7th Floor, 1000 Brussels, Belgium
    Cancer 97:40-5. 2003
    ..The potential cardiotoxicity of the doxorubicin-paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies...
  95. ncbi Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results
    Nigel J Bundred
    South Manchester University Hospital, Academic Surgery, Education and Research Center, Manchester, UK
    Cancer 112:1001-10. 2008
    ..This study evaluated an immediate or delayed strategy of bone protection therapy with zoledronic acid...
  96. ncbi Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial
    Lee S Rosen
    Developmental Therapeutics, Cancer Institute Medical Group, Santa Monica, California 90095, USA
    Cancer 98:1735-44. 2003
    ..The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma...
  97. ncbi Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
    Lee S Rosen
    Cancer Institute Medical Group, Santa Monica, California, USA
    Cancer 100:36-43. 2004
    ..Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial...
  98. ncbi Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study
    T R Jeffry Evans
    Cancer Research United Kingdom Department of Medical Oncology, University of Glasgow, Beatson Laboratories, Garscube Estate, Switchback Rd, Glasgow G61 1BD, United Kingdom
    J Clin Oncol 23:2988-95. 2005
    ..CONCLUSION In contrast to the positive results reported for sequential docetaxel after AC as primary chemotherapy of breast cancer, our data do not suggest a benefit for simultaneous AD over AC...
  99. ncbi Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Clin Oncol 28:8-16. 2005
    ..There were no significant cost differences between patients receiving zoledronic acid and those receiving pamidronate...
  100. ncbi A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
    Jean Jacques Body
    Department of Medicine, Institut Jules Bordet, Brussels, Belgium
    Clin Cancer Res 12:1221-8. 2006
    ..Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, was developed to treat patients with skeletal diseases...
  101. ncbi Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours
    Daniele Santini
    Clinical Oncology, University Campus Bio Medico, 00155 Rome, Italy
    Oncol Rep 15:1351-7. 2006
    ..Future clinical trials should be designed to prospectively evaluate the prognostic role of reduction of betaCTX and VEGF in response to ZOL to predict clinical and skeletal outcome...